 |  |  |  |  |  |
Number of Patients Who Achieved a 40% Reduction from Baseline
VAS 12 Week Post Treatment
Orthometrix Orbasone: Summary of Safety and Effectiveness Data
P040039 (http://www.fda.gov/cdrh/PDF4/p040039b.pdf)
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
| Clinical Results |
|||||||||||||||
| Orbasone Percent Improvement – Plantar Fasciitis Number of Patients Who Achieved a 40% Reduction from Baseline VAS 12 Week Post Treatment Orthometrix Orbasone: Summary of Safety and Effectiveness Data P040039 (http://www.fda.gov/cdrh/PDF4/p040039b.pdf) |
|||||||||||||||
| % Improvement |
|
| Active Treatment |
69.2% |
| Sham Treatment |
37.0% |
